Clinical Trial Update: A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 trial assessing MT-0814 for age-related macular degeneration was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• MT-0814

Snippet

Sponsor: Senju Pharmaceutical Co., Ltd. | Conditions: Age-related Macular Degeneration | Phase 2 | Status: TERMINATED | Results posted: 2021-04-20